Repository logo
 

Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity

Published version
Peer-reviewed

Change log

Abstract

Abstract: Aggregation of alpha-synuclein (α-Syn) drives Parkinson’s disease (PD), although the initial stages of self-assembly and structural conversion have not been directly observed inside neurons. In this study, we tracked the intracellular conformational states of α-Syn using a single-molecule Förster resonance energy transfer (smFRET) biosensor, and we show here that α-Syn converts from a monomeric state into two distinct oligomeric states in neurons in a concentration-dependent and sequence-specific manner. Three-dimensional FRET-correlative light and electron microscopy (FRET-CLEM) revealed that intracellular seeding events occur preferentially on membrane surfaces, especially at mitochondrial membranes. The mitochondrial lipid cardiolipin triggers rapid oligomerization of A53T α-Syn, and cardiolipin is sequestered within aggregating lipid–protein complexes. Mitochondrial aggregates impair complex I activity and increase mitochondrial reactive oxygen species (ROS) generation, which accelerates the oligomerization of A53T α-Syn and causes permeabilization of mitochondrial membranes and cell death. These processes were also observed in induced pluripotent stem cell (iPSC)–derived neurons harboring A53T mutations from patients with PD. Our study highlights a mechanism of de novo α-Syn oligomerization at mitochondrial membranes and subsequent neuronal toxicity.

Description

Journal Title

Nature Neuroscience

Conference Name

Journal ISSN

1097-6256
1546-1726

Volume Title

25

Publisher

Nature Publishing Group US

Rights and licensing

Except where otherwised noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/
Sponsorship
RCUK | Engineering and Physical Sciences Research Council (EPSRC) (EP/L016559/1, EP/L016559/1)
Government Council on Grants, Russian Federation (075-15-2019-1877)
RCUK | Medical Research Council (MRC) (MR/T008199/1, MR/T008199/1)
Alzheimer’s Research UK (ARUK) (ARUK-EG2018B-004))
Wellcome Trust (Wellcome) (WT089698)